KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Retained Earnings: 2017-2024

Historic Retained Earnings for Moderna (MRNA) over the last 8 years, with Dec 2024 value amounting to $10.0 billion.

  • Moderna's Retained Earnings fell 27.91% to $8.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $8.0 billion, marking a year-over-year decrease of 27.91%. This contributed to the annual value of $10.0 billion for FY2024, which is 26.17% down from last year.
  • As of FY2024, Moderna's Retained Earnings stood at $10.0 billion, which was down 26.17% from $13.6 billion recorded in FY2023.
  • Moderna's Retained Earnings' 5-year high stood at $18.3 billion during FY2022, with a 5-year trough of -$2.2 billion in FY2020.
  • Over the past 3 years, Moderna's median Retained Earnings value was $13.6 billion (recorded in 2023), while the average stood at $14.0 billion.
  • In the last 5 years, Moderna's Retained Earnings plummeted by 49.95% in 2020 and then soared by 543.76% in 2021.
  • Moderna's Retained Earnings (Yearly) stood at -$2.2 billion in 2020, then soared by 543.76% to $10.0 billion in 2021, then soared by 83.97% to $18.3 billion in 2022, then decreased by 25.73% to $13.6 billion in 2023, then fell by 26.17% to $10.0 billion in 2024.